AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03682107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System
Study NCT02194361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthocyan capsules
Description: Bilberry extract capsules, 160 mg (25% anthocyanosides)
Study NCT03293147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPLC-MS/MS-guided intervention
Description: The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
Study NCT02194361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03524651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Blisters of 10 capsules containing 150 mg of ferrous sulfate.
Study NCT03524651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fe-ASP
Description: Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.
Study NCT03524651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.
Study NCT03524651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fe-ASP
Description: Blisters of 10 capsules containing inactive ingredients of Microfer.
Study NCT03806673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcaine
Description: epidural block
Study NCT03076632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical plus transcranial stimulation
Description: Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
Study NCT03293147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for hypertensive patients
Study NCT01341106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with entecavir(Baraclude®)
Description: Patient will be daily treated with 1 tablet of entecavir per oral
Study NCT03076632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical stimulation plus hand/wrist exercise
Description: Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.
Study NCT03076632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyographic (EMG)-triggered (closed-loop) stimulation
Description: Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
Study NCT04688385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multipeptide Vaccine+ XS15
Description: Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as > 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
Study NCT02726724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 observer
Study NCT01079416 — intervention group
Intervention type: DEVICE
Intervention: Capsule endoscopy, Esophagogastroduodenoscopy
Study NCT03910218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCM4HIV
Description: Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
Study NCT00812773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915
Description: Investigational Product
Study NCT03910218 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
Study NCT02832986 — intervention group
Intervention type: OTHER
Intervention: Medical Questionary
Description: The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment
Study NCT04815005 — intervention group
Intervention type: OTHER
Intervention: Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
Description: Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
Study NCT04532749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Participants will receive Seltorexant tablets.
Study NCT04532749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets.
Study NCT01848769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 pMDI + AC Plus
Description: Four inhalations for a total dose of BDP/FF 200/24 mcg
Study NCT01848769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP + AC Plus
Description: Four inhalations for a total dose of BDP 200 mcg
Study NCT01848769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol + AC Plus
Description: Four inhalations for a total dose of Formoterol 24 mcg
Study NCT00526214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib medication
Description: In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
Study NCT02551601 — intervention group
Intervention type: OTHER
Intervention: measure subfoveal choroidal thickness
Description: measure subfoveal choroidal thickness using optical coherence tomography
Study NCT04471506 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: interval training
Description: Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).
Study NCT04471506 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diet recommendations
Description: the control group will follow diet recommendations for 12 weeks
Study NCT04471506 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mindfulness breathing
Description: Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
Study NCT03084601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide, Iodoform, paste
Description: mixture of calcium hydroxide and iodoform
Study NCT03084601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-mixtatin
Description: 3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
Study NCT02826005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT00638950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 LC-PUFA
Description: Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
Study NCT00638950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo products were commercial dairy products with comparable fat contents.
Study NCT02530034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
Description: Given IV
Study NCT02530034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02530034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02908594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Exercise Peddler 3000, Medi-Bike, Taiwan
Description: A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes.
Study NCT02545465 — intervention group
Intervention type: DRUG
Intervention: Riociguat (Adempas, BAY63-2521)
Description: As per the treating physicians discretion
Study NCT02434666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC-201
Study NCT01114191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
Study NCT01114191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 400 mg days 6-11
Study NCT04130633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vapor (distilled water)
Study NCT04130633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor
Study NCT04130633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Pinene
Description: Pure alpha-pinene vapor
Study NCT04259008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manganese omission
Description: Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
Study NCT04259008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 mCg/kg/day manganese from Multitrace-4 Neonatal.
Description: 5 mCg/kg/day manganese from Multitrace-4 Neonatal.
Study NCT00731146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Minimum Effective Anesthetic Volume
Description: Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
Study NCT04298229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
Study NCT00731146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Stimulator Minimum Effective Anesthetic Volume
Description: Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
Study NCT04298229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized Diuretic Therapy
Description: Structured usual care arm with protocolized diuretic therapy based on urine output.
Study NCT04298229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized Diuretic Therapy
Description: Structured usual care arm with protocolized diuretic therapy based on urine output.
Study NCT04642326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Group: experimental - UVC Therapy applied
Description: in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
Study NCT01556503 — intervention group
Intervention type: DEVICE
Intervention: VivaScope System
Description: VivaScope System, Model#s 1500 and 2500
Study NCT03116789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: Two capsules for daily
Study NCT00243477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg or placebo once a day
Study NCT00243477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg or placebo once a day
Study NCT02227420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100mg s.c. x 5
Study NCT00142207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent preventive treatment:sulphadoxine-pyrimethamine
Description: Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
Study NCT00142207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insecticide-treated mosquito bed net
Description: Insecticide-treated mosquito bed net
Study NCT00777439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Domperidone
Description: 10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
Study NCT01208376 — intervention group
Intervention type: OTHER
Intervention: Fibroscan
Description: Fibroscan and Serum Fibrose-marker
Study NCT01233284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide 2.5µg once daily
Description: Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
Study NCT01233284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium matching Placebo once daily
Description: Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
Study NCT01233284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide high dose once daily
Description: Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
Study NCT01233284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide 1.25µg once daily
Description: IMP
Study NCT02974764 — intervention group
Intervention type: OTHER
Intervention: No intervention/exposures
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esterase wholegrain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Esterase wholegrain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.
Study NCT03928821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121
Description: 20 mg/kg administered intravenously
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.
Study NCT01287403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.
Study NCT04500925 — intervention group
Intervention type: PROCEDURE
Intervention: UNILATERAL THYROIDECTOMY
Study NCT03902158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: The patient will wear virtual reality glasses during anesthesia
Study NCT03928821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400
Description: 20 mg/kg administered intravenously
Study NCT03928821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: 20 mg/kg administered intravenously
Study NCT03902158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction techniques
Description: The patient will undergo distraction techniques
Study NCT03987165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby.
Study NCT02028182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyral®
Description: Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
Study NCT02198040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: * 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin
Study NCT03928821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 20 mg/kg administered intravenously
Study NCT02935478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embospheres Microspheres
Description: Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
Study NCT03612388 — intervention group
Intervention type: PROCEDURE
Intervention: use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
Description: use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
Study NCT03760809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5μg／kg
Description: Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.